Swiss economy. Global risks to weigh on Swiss growth

Size: px
Start display at page:

Download "Swiss economy. Global risks to weigh on Swiss growth"

Transcription

1 Global risks to weigh on Swiss growth Chief Investment Office WM 8 November 8 7: am GMT+: Translation: November 8 Alessandro Bee, Economist, alessandro.bee@ubs.com The Swiss economy is likely to grow by.6% next year. This corresponds to long-term trend growth but is significantly lower than our GDP growth forecast of.9% for this year. Export and investment growth is likely to slow next year on the back of a weaker global outlook. In contrast, consumer demand may benefit from a stronger labor market. An improving capacity utilization and high oil prices are likely to support inflation. Various economic and geopolitical uncertainties weigh on next year s outlook. The biggest risks for the Swiss economy stem from Italy s fiscal policy, a significant cooling of the European economy and the possibility of a global trade war. Swiss economic growth has accelerated significantly since mid-7. In the last five quarters, GDP expanded by.8% on average, considerably above its long-term quarterly growth rate of.45%. The current solid momentum of Swiss growth is matched only by the rebound after the Great Recession (Figure ). Swiss franc, global economy and World Cup bolstered Swiss growth Economic growth has been boosted by a rebound in the export industry (Figure ), which in turn stimulated manufacturing. While in 5 and 6 most export sectors were ailing and only the pharmaceutical industry was thriving, export growth broadened markedly in the last quarters (Figure ). Manufacturing activity benefited from robust growth in the global economy in the previous quarters and from the weaker Swiss franc in H8. While EURCHF oscillated around.7 in H7, it nearly hit the. mark this April. 8 s major sporting events, the Olympic Winter Games and the FIFA World Cup, further supported Swiss growth. Switzerland is home to many sports associations headquarters. Whenever major sporting events take place, revenues stemming from TV and merchandising fees flow into Switzerland and bolster Swiss activity. This year s two major sporting events may have added up to. ppt to GDP growth. Stronger economy supports jobs Swiss economic growth is heavily influenced a by a few sectors which are important in terms of value added but which employ relatively few workers, namely the pharmaceutical industry and commodity trading. This raises the question whether the current strong GDP growth only exists in national accounting terms or whether it also affects the real word, i.e. employment. Fig. : Swiss GDP growth accelerates strongly GDP growth quarter-on-quarter and year-on-year, in % GDP growth yoy, left hand scale GDP growth qoq, right hand scale Sources: Macrobond, SECO, UBS Fig. : Swiss economy gaining from a rebound in manufacturing Contribution to GDP growth from manufacturing and services, in percentage points.5%.%.5%.%.5%.%.5%.% -.5% -.% Contribution manufacturing Contribution services Rest Sources: Macrobond, SECO, UBS GDP growth This report has been prepared by UBS Switzerland AG. Please see important disclaimers and disclosures at the end of the document.

2 Indeed, the Swiss economy has recorded not only a strong pickup in activity but also a healthy rebound in employment (Figure 4). The shift from pharmaceutical-driven to more broad-based export growth has boosted job creation in manufacturing, which in Q8 recorded the strongest employment gains in years. Switzerland s growth surge in H8 will help the economy to expand by.9% this year (Figure 5), which is the strongest growth rate since. GDP growth that is considerably above potential has also improved capacity utilization. After the Swiss National Bank (SNB) abolished the EURCHF currency floor in January 5, capacity utilization fell strongly and the output gap (the difference between realized GDP growth and long-term trend growth) widened. The recent acceleration in activity has helped to close the output gap. We estimate that the Swiss economy is currently running.8 ppt above long-term capacity constraints (Figure 6). Swiss outlook clouds over While Swiss economic growth in H8 was buoyant, the outlook for 9 is clouding over. Global economic growth is likely to slow in the coming quarters, in our view. In the US and China, negative side effects of the trade tensions may hamper growth. Eurozone growth is also set to slow, as the current above-par growth rates are not likely to continue indefinitely and leading indicators already point to weaker growth. While we expect global growth near 4% this year, we anticipate it to slow to about.5% next year. Various global risks including a global trade war, a hard landing in China, a hard Brexit, and a resurrection of the euro crisis are fueling uncertainty for Swiss companies. Meanwhile, the fragile geopolitical situation in the Middle East points to upside risks in the price of oil. Export-oriented Swiss companies may hesitate to invest in this environment, which, in turn, could weigh on growth. The Swiss franc has regained strength in the last months. While we do not foresee a longer-term appreciation of the Swiss franc, this bout of strength in combination with a slowing global economy is likely to weigh on Swiss growth. Swiss economic growth may slip to.6% in 9 (Figure 5). While such a drop seems like a sharp deterioration compared with 8, next year s expected growth corresponds to Swiss trend growth and so is a far cry from a major growth slump. Global political risks may burden Swiss companies willingness to invest but are unlikely to cause further damage, as we do not expect the aforementioned risk scenarios to materialize. That said, should one of the risks come to pass, Swiss growth may take a significantly stronger hit. We worry most about a full-blown trade war, which, according to our simulations, could reduce global growth to just % and would point to Swiss growth clearly below trend growth. Fig. : Export growth broadens in H8 Export growth of the pharmaceutical industry and of the Top 6 sectors ex pharmaceuticals (chemistry, machines & electronics, metals, precision instruments, watches) in %, -months-average Total exports Pharmaceutical exports Top 6 ex pharmaceuticals Sources: Macrobond, FCA, UBS Fig. 4: Robust employment growth in Q8 Employment growth year-on-year in manufacturing and services, in % Sources: Macrobond, BfS, UBS Total Manufacturing Services Fig. 5: Slower growth in 9 inflation to remain stable Swiss GDP growth and inflation with UBS forecasts for 8 and 9, in % E 9E E 9E GDP growth Inflation Sources: Macrobond, UBS UBS CIO WM 8 November 8

3 Slower export and investment growth This year s robust global conditions favor cycle-sensitive exporters like electronics, machines and metals. But these sectors may suffer most from a global slowing going forward. A stronger Swiss franc is likely to hurt Swiss tourism, the most currency-sensitive export sector. Pharmaceutical exports, on the other hand, generally remain almost untouched by changes in economic growth or the currency situation. The biggest threat to the pharmaceutical industry is posed by a major revamp of the US health care system, if such a revamp is associated with major cost-cutting measures. Investments in equipment are hurt twofold by a slowing global economy. First, a deceleration in export growth, and so in manufacturing growth, will also reduce the need for capacity expansion and the need to invest in equipment. Second, heightened global uncertainty may force companies to defer investment plans. Rising vacancies should slow construction investment Swiss domestic risks are less pronounced than global ones but do exist, particularly in the real estate market. Vacancy rates are rising markedly and may hit new all-time highs next year, which in turn could cloud the outlook for the construction sector. The recent drop in building applications also points to a cooling in construction (Figure 7). But whether construction activity really falls given fading demand is uncertain, as it has proven resilient to rising vacancies in recent years. In the current environment, institutional investors are prepared to accept some vacancies in their real estate portfolios rather than turn to negative interest rates on cash holdings. Construction activity is likely to only slow in the course of 9 what could amplify imbalances in the Swiss real estate market in the short term. On the household side, there is significant room for improvement. Private consumption has shown sub-par growth in the last two years, and we anticipate consumer demand will advance by only.% this year. Robust employment gains and a turnaround in the pace of net immigration should bolster consumer demand in the medium term. But higher inflation rates may hold back households' willingness to consume in the short term. Inflation rates around % could turn nominal wage gains of.8% into real wage losses. Nominal wage growth fluctuated between.5 and % in recent years (Figure 8). An improving labor market could push wage growth to the upper end of this band and, longer term, above the % mark. That said, we expect nominal wages and the inflation rate to grow both by % next year what implies a stagnation in real wages. Consumer-oriented sectors to improve only medium term (Author: Sibille Duss) Swiss exports were able to distinguish themselves from the pharmaceutical industry in recent quarters. The metal and watch industries reported strong gains of % and %, respectively, from January to August compared to the same period of last year. Fig. 6: Output gap of Swiss economy closed Output gap (materialized GDP growth less GDP trend growth), in % of GDP Sources: Macrobond, UBS Fig. 7: Significant drop in building applications Building applications per quarter and 5-year average 6' 4' ' ' 5 year average 8' Sources: Docu Media, UBS Fig. 8: Nominal wages to rise slightly Wage growth in nominal terms, in %, with UBS forecasts for 8 and Sources: BfS, UBS UBS CIO WM 8 November 8

4 Sectors with a high export share like the MEM-industry (with an export share of almost 8%) would suffer most from the consequences of the trade dispute. Through second-round effects, more protectionism could also hurt suppliers, e.g. the Swiss suppliers for the German car industry. These sectors do not heavily export to the US or China but are supplying exporters that have exposure to these markets. Besides a trade war, an appreciation of the Swiss franc serves as one of the major risks for many sectors. A stronger Swiss franc will weigh not only on the industry sector, but also on tourism and retail trade. A study by the KOF Swiss Economic Institute suggests that a % increase in prices leads to an 8% decrease in overnight stays from German tourists, the most price-sensitive guests. The retail and wholesale sector and logistics are likely to feel the still sub-par growth rate of consumer demand. We expect consumer demand to improve in the medium term, which may also sustain these sectors, but structural challenges will persist, especially for retail. Stable inflation capacity utilization as a future driver Inflation gained momentum in H8 and in the summer reached levels not seen since. The latest rise in inflation was driven by rising oil prices. The softer franc in H8 also boosted import prices (Figure 9). Finally, improving capacity utilization led to some domestic price pressures, which are reflected in a modest rise in core inflation. We expect consumer prices to rise by % in 8. Oil prices are set to rise further in the coming months and should underpin inflation rates in the short term. The Swiss franc is likely to weaken in the course of 9 and should drive inflation in the second half of next year. So we expect Swiss inflation to remain at % in 9, as well. While we regard oil prices and the Swiss franc as the main inflation drivers for this and next year, capacity utilization could become the prime driver in. An improving economy will return some bargaining power from buyers to sellers and from companies to their employees. The resulting wage gains should support core inflation and keep inflation around % in, even as the impact from oil prices and the currencies fades. Labor market on the mend despite all the noise Labor market indicators paint a rosy, but sometimes conflicting, picture of the Swiss job market. Full-time equivalent employment growth accelerated significantly in Q8. More than 75, new jobs were created from mid-7 to mid-8. The service industry added more than 6, new jobs,, jobs were created in manufacturing, construction also added jobs. Job growth in manufacturing benefited from the watch industry, where 5, new jobs were created. Unemployment rates have evolved inconsistently. The unemployment rate published by the SECO, which is based on unemployed persons registered at the regional job service centers, dropped sharply (Figure ). Fig. 9: Inflation driven by oil and import goods Contribution to total inflation by oil prices, import goods ex petroleum and domestic goods, in percentage points Jun 6 Dez 6 Jun 7 Dez 7 Jun 8 Domestic goods Import goods ex petroleum Sources: Macrobond, BfS, UBS Petroleum goods Total Fig. : ILO and SECO unemployment rates diverging Unemployment rates defined by ILO and unemployment rates published by the SECO, in % Unemployment SECO, seasonal adjusted Unemployment ILO, seasonal adjusted Sources: Marcobond, BfS, SECO, UBS UBS CIO WM 8 November 8 4

5 But only half of the drop is economically relevant, as the other half is due to a technical change in regional job service centers and does not reflect stronger labor market conditions. Even so, the fall in the SECO unemployment rate points to a noticeable improvement in the Swiss labor market in H8, even after taking into account the methodological changes. By contrast, the unemployment rate generated by following the definition of the International Labor Organization (ILO) has not shown any improvement yet. It remained near 5% in Q8. The different behavior of the two unemployment rates is surprising since in the past they have moved in sync. One explanation for this difference may be that, at the beginning of a labor market recovery, people who are out of the job market for a long time usually find it harder to reenter the labor market than short-term unemployed people. The ILO unemployment rate differs from the SECO rate in that it includes more long-term job seekers. Leading indicators for the Swiss labor market point to a continuation of the labor market's recovery. Indicators from Adecco, KOF and the PMIs show similar conditions today as were seen in or 4, when the Swiss labor market recovered markedly (Figure ). In 9, employment growth is likely to slow due to softer growth. While GDP growth at.9% in 8 implies annual employment growth at nearly %, our 9 GDP growth forecast of.6% points to employment advancing by about %. As SECO unemployment rates are already at very low levels, we only foresee a slight drop next year, but we hope to see significant improvement in the ILO rate to 4.4% in 9, as a more advanced labor market recovery also gives long-term unemployed job seekers more opportunities to reenter the market. Net immigration (immigration minus emigration) remained near the levels of last year and should end the year slightly above the 5, mark (Figure ). Given the strong rebound in employment and the tighter labor market in Switzerland (at least according to SECO readings), this is a clear indication that improvements in labor market conditions in the Eurozone reduce the push factor for foreign workers to move to Switzerland. A further improvement in the labor market is likely to accelerate net immigration next year, albeit not to levels seen five years ago when labor markets in the Eurozone were in significantly worse shape than today. All eyes on a possible corporate tax OASI deal vote Domestic risks for the Swiss economy are emerging not only from the real estate market, but also from economic policy. In May 9 important domestic issues will arrive at the ballot box when Swiss voters may (it s still not clear yet whether a referendum will come about) cast their votes on a combined proposal reforming the old age and survivor insurance (OASI) and corporate taxation. The intensification of the global tax competition has increased the urgency of a reform in corporate taxation. Tax cuts initiated under US President Donald Trump may trigger a downward spiral in international corporate taxation. Switzerland, a long-time leader in this area, faces the risk of falling behind. Should the proposal fail, uncertainty stemming from global risks may be amplified and investments could be hurt. Fig. : Labor market indicators point to further improvement Labor market indicators, normalized deviations from the mean Adecco PMI manuf. PMI non-manuf. KOF Sources: Macrobond, UBS Fig. : Net immigration on last year s level Evolution of net immigration (permanent and non-permanent population) in the course of the year (-) 6' 5' 4' ' ' ' Sources: SEM, UBS Table : UBS economic forecasts Switzerland % change yoy in real terms, adjusted for seasonal and calendar effects Forecasts UBS Level* F 9F Gross domestic product Private consumption Government spending Capital spending Construction Equipment Exports** Imports** Inflation Unemployment rate*** *Year 7 (in CHF billion at current prices) **Without valuables and non-monetary gold ***Annual average P: UBS forecast Sources: UBS UBS CIO WM 8 November 8 5

6 The relationship between Switzerland and the European Union is also a major topic. The self-determination initiative (Selbstbestimmungsinitiative) will be put to the vote on 5 November. If approved, negotiating a new framework for the bilateral agreement with the EU (Rahmenabkommen) will become more difficult. The initiative for limiting immigration (Beschränkungsinitiative) aims to repeal the free movement of people between Switzerland and the EU and could if approved end the bilateral agreements. However, this initiative will not come to a vote before. Even if these initiatives are rejected at the ballot box the prospect of a further deepening of relationships with the EU is modest at best. As long as the EU is engaged in negotiating the terms of the UK departure from the EU and possibly a new trade deal, there is little hope for a substantial step forward. Only after the Brexit deal is settled will Swiss politicians know whether and where there is leeway to negotiate. Looking further ahead, Swiss general elections will take place in October 9 but are unlikely to have a significant impact on Swiss economic policies. There are no clear-cut coalitions in Swiss politics with alliances changing across topics and issues. The impact of the parliament is also limited because of public voting. Today the National Council is dominated by a thin margin by the FDP and the Swiss People s Party (Figure ), while Christian Democrats and Socialdemocrats have a majority in the Council of States (Figure 4). Next year s elections could bring the majority back to the centerleft in both chambers. But this potential shift would only be a minor change in the Swiss political landscape as, in a majority of economic issues, the separation line runs between the center-right parties and the left. Fig. : Swiss People s Party and FDP have a slight majority in the National Council Current distribution of the seats in the National Council Socialdemocrats 4 Green Liberals 7 BDP 7 Christian Democrats Sources: UBS Greens FDP Swiss People's Party 68 Fig. 4: Center-right parties dominating the Council of States Current distribution of the 46 seats in the Council of States Socialdemocrats Green Party Swiss People's Party 6 BDP FDP Sources: UBS Christian Democrats UBS CIO WM 8 November 8 6

7 Appendix Generic investment research Risk information: UBS Chief Investment Office's investment views are prepared and published by Global Wealth Management a Business Division of UBS Switzerland AG (regulated by FINMA in Switzerland), its subsidiaries or affiliates ("UBS"). The investment views have been prepared in accordance with legal requirements designed to promote the independence of investment research. This material is for your information only and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this material were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any forecasts, estimates and prices indicated are current as of the date of this report, and are subject to change without notice. The market prices provided in performance charts and tables are closing prices on the respective principal stock exchange. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria. In no circumstances may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees. By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or otherwise rely on any of the Information for any of the above purposes. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instruments in the capacity of principal or agent, or provide any other services or have officers, who serve as directors, either to/ for the issuer, the investment instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities) made by UBS and its employees may differ from or be contrary to the opinions expressed in UBS research publications. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and Options trading is not suitable for every investor as there is a substantial risk of loss, and losses in excess of an initial investment may occur. Past performance of an investment is no guarantee for its future performance. Additional information will be made available upon request. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in general or with reference to specific client's circumstances and needs. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein. This material may not be reproduced or copies circulated without prior authority of UBS. Unless otherwise agreed in writing UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS accepts no liability whatsoever for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. Forecasts and estimates are current only as of the date of this publication and may change without notice. For information on the ways in which UBS CIO WM manages conflicts and maintains independence of its investment views and publication offering, and research and rating methodologies, please visit Additional information on the relevant authors of this publication and other CIO publication(s) referenced in this report; and copies of any past reports on this topic; are available upon request from your client advisor. External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties. Australia: This notice is issued by UBS AG ABN (Holder of Australian Financial Services Licence No 87): This Document is issued and distributed by UBS AG. This is the case despite anything to the contrary in the Document. The Document is intended for use only by Wholesale Clients as defined in section 76G ( Wholesale Clients ) of the Corporations Act (Cth) ( Corporations Act ). In no circumstances may the Document be made available by UBS AG to a Retail Client as defined in section 76G of the Corporations Act. UBS AG s research services are only available to Wholesale Clients. The Document is general information only and does not take into account any person s investment objectives, financial and taxation situation or particular needs. Austria: This publication is not intended to constitute a public offer under Austrian law, but might be made available for information purposes to clients of UBS Europe SE, Niederlassung Österreich, with place of business at Wächtergasse, A- Wien. UBS Europe SE, Niederlassung Österreich is a branch of UBS Europe SE, a credit institution constituted under German Law in the form of a Societas Europaea, duly authorized by the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin), and is subject to the joint supervision of BaFin, the central bank of Germany (Deutsche Bundesbank), as well as of the Austrian supervisory authority (Finanzmarktaufsicht, FMA), to which this publication has not been submitted for approval.. Bahrain: UBS is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, Clients have no protection under local banking and investment services laws and regulations. Brazil: Prepared by UBS Brasil Administradora de Valores Mobiliários Ltda, entity regulated by Comissão de Valores Mobiliários ("CVM"). Canada: In Canada, this publication is distributed to clients of UBS Wealth Management Canada by UBS Investment Management Canada Inc.. Czech Republic: UBS is not a licensed bank in Czech Republic and thus is not allowed to provide regulated banking or investment services in Czech Republic. This material is distributed for marketing purposes. Denmark: This publication is not intended to constitute a public offer under Danish law, but might be distributed by UBS Europe SE, Denmark Branch, filial af UBS Europe SE, with place of business at Sankt Annae Plads, 5 Copenhagen, Denmark, registered with the Danish Commerce and Companies Agency, under the No UBS Europe SE, Denmark Branch, filial af UBS Europe SE is a branch of UBS Europe SE, a credit institution constituted under German Law in the form of a Societas Europaea, duly authorized by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin). UBS Europe SE, Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the BaFin, the central bank of Germany (Deutsche Bundesbank) and the Danish Financial Supervisory Authority (DFSA) (Finanstilsynet), to which this document has not been submitted for approval. France: This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of , 69, boulevard Haussmann F-758 Paris, R.C.S. Paris B , to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution". Germany: The issuer under German Law is UBS Europe SE, Bockenheimer Landstrasse -4, 66 Frankfurt am Main. UBS Europe SE is authorized and regulated by the "Bundesanstalt für Finanzdienstleistungsaufsicht". Hong Kong: This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. India: Distributed by UBS Securities India Private Ltd. /F, North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 45. Phone: SEBI Registration Numbers: NSE (Capital Market Segment): INB954, NSE (F&O Segment) INF954, BSE (Capital Market Segment) INB9547. Israel: UBS Switzerland AG is registered as a Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd, a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd is a licensed Portfolio Manager which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication shall not replace any investment advice and/or investment marketing provided by a relevant licensee which is adjusted to your personal needs. Italy: This publication is distributed to the clients of UBS Europe SE, Succursale Italia, Via del Vecchio Politecnico, - Milano, the branch of a German bank duly authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht to the provision of financial services and supervised by "Consob". Jersey: UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey, they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland whose registered offices are at Aeschenvorstadt, CH-45 Basel and Bahnhofstrasse 45, CH 8 Zurich. UBS AG, Jersey Branch's principal place business is, IFC Jersey, St Helier, Jersey, JE BX. Luxembourg: This publication is not intended to constitute a public offer under Luxembourg law, but might be made available for information purposes to clients of UBS Europe SE, Luxembourg Branch, with place of business at A, Avenue J. F. Kennedy, L-855 Luxembourg. UBS Europe SE, Luxembourg Branch is a branch of UBS Europe SE, a credit institution constituted under German Law in the form of a Societas Europaea, duly authorized by the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin), and is subject to the joint supervision of BaFin, the central bank of Germany (Deutsche Bundesbank), as well as of the Luxembourg supervisory authority, the Commission de Surveillance du Secteur Financier (the "CSSF"), to which this publication has not been submitted for approval. Mexico: This document has been distributed by UBS Asesores México, S.A. de C.V., a company which is not part of UBS Grupo Financiero, S.A. de C.V. or of any other Mexican financial group and whose obligations are not guaranteed by any third party. UBS Asesores México, S.A. de C.V. does not guarantee any yield whatsoever. Netherlands: This publication is not intended to constitute a public offering or a comparable solicitation under Dutch law, but might be made available for information purposes to clients of UBS Europe SE, Netherlands branch, a branch of a German bank duly authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht for the provision of financial services and supervised by "Autoriteit Financiële Markten (AFM) in the Netherlands, to which this publication has not been submitted for approval. New Zealand: This notice is distributed to clients of UBS Wealth Management Australia Limited ABN (Holder of Australian Financial Services Licence No. 7), Chifley Tower, Chifley Square, Sydney, New South Wales, NSW, by UBS Wealth Management Australia Ltd. You are being provided with this UBS publication or material because you have indicated to UBS that you are a client certified as a wholesale investor and/or an eligible investor ("Certified Client") located in New Zealand. This publication or material is not intended for clients who are not Certified Clients ("Non-Certified Clients"), and if you are a Non-Certified Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective directors, officers, agents and advisers (each a "Relevant Person") for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. Saudi Arabia: This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi Arabian closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 578 having its registered office at Tatweer Towers, P.O. Box 7574, Riyadh 588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority of Saudi Arabia. Singapore: Please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. ) and a wholesale bank licensed under the Singapore Banking Act (Cap. 9) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. UBS CIO WM 8 November 8 7

8 Appendix Spain: This publication is distributed to its clients by UBS Europe SE, Sucursal en España, with registered office at Calle María de Molina 4, C.P. 86, Madrid, entity supervised by Banco de España and the Bundesanstalt für Finanzdienstleistungsaufsicht. UBS Europe SE, Sucursal en España is a branch of UBS Europe SE, a credit institution constituted in the form of a Societas Europaea authorized and regulated by the Bundesanstalt für Finanzdienstleistungsaufsich. Sweden: This publication is not intended to constitute a public offer under Swedish law, but might be distributed by UBS Europe SE, Sweden Bankfilial with place of business at Regeringsgatan 8, 5 Stockholm, Sweden, registered with the Swedish Companies Registration Office under the Reg. No UBS Europe SE, Sweden Bankfilial is a branch of UBS Europe SE, a credit institution constituted under German Law in the form of a Societas Europaea, duly authorized by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin). UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the BaFin, the central bank of Germany (Deutsche Bundesbank) and the Swedish financial supervisory authority (Finansinspektionen), to which this document has not been submitted for approval. Taiwan: This material is provided by UBS AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. Thailand: This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly delete the and inform UBS immediately. The material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the material, and by receiving the material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. UAE: This research report is not intended to constitute an offer, sale or delivery of shares or other securities under the laws of the United Arab Emirates (UAE). The contents of this report have not been and will not be approved by any authority in the United Arab Emirates including the UAE Central Bank or Dubai Financial Authorities, the Emirates Securities and Commodities Authority, the Dubai Financial Market, the Abu Dhabi Securities market or any other UAE exchange. This material is intended for professional clients only. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS AG/UBS Switzerland AG is not licensed to provide banking services in the UAE by the Central Bank of the UAE nor is it licensed by the UAE Securities and Commodities Authority. The UBS AG Representative Office in Abu Dhabi is licensed by the Central Bank of the UAE to operate a representative office. UK: Approved by UBS AG, authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to private clients of UBS London in the UK. Where products or services are provided from outside the UK, they will not be covered by the UK regulatory regime or the Financial Services Compensation Scheme. USA: This document is not intended for distribution into the US, to US persons, or by US-based UBS personnel. UBS Securities LLC is a subsidiary of UBS AG and an affiliate of UBS Financial Services Inc., UBS Financial Services Inc. is a subsidiary of UBS AG. Version 8/8. CIO UBS 8.The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved. UBS CIO WM 8 November 8 8

Swiss Chartset. Last update: 07 September 2018

Swiss Chartset. Last update: 07 September 2018 Swiss Chartset Last update: 07 September 2018 This report has been prepared by UBS Switzerland AG. Please see the important disclaimer at the end of the document. This chartset should be read in conjunction

More information

UBS Compensation Survey 2017

UBS Compensation Survey 2017 Public UBS Compensation Survey 2017 Outlook Dr. Daniel Kalt UBS Chief Economist & Chief Investment Officer Switzerland October 26, 2016 Economic environment Real Gross Domestic Product (Index Q1 2005 =

More information

Chief economist's comment

Chief economist's comment Chief economist's comment What's happening everywhere else? Chief Investment Office WM 28 January 2019 7:47 pm GMT Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com The growth in demand in

More information

UK economy. BREXIT: into the final furlong. Dean Turner, CFA Economist CIO WM UK UBS Wealth Management. Source: istock

UK economy. BREXIT: into the final furlong. Dean Turner, CFA Economist CIO WM UK UBS Wealth Management. Source: istock UK economy BREXIT: into the final furlong Dean Turner, CFA Economist CIO WM UK UBS Wealth Management Source: istock March 2016 The polls have narrowed, but "remain" still in the lead. Our BREXIT probability

More information

Chief economist's comment

Chief economist's comment Chief economist's comment No confidence in confidence data? Chief Investment Office WM 20 April 2017 Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com Financial markets love confidence numbers.

More information

Chief economist's comment

Chief economist's comment Chief economist's comment What can we forecast about next year? Chief Investment Office WM 11 December 2017 2:01 pm GMT Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com Economic forecasts

More information

Swiss real estate market

Swiss real estate market UBS Swiss Real Estate Index 4Q- Chief Investment Office WM 7 February 2018 Translation: Matthias Holzhey, Economist, matthias.holzhey@ubs.com; Claudio Saputelli, Economist, claudio.saputelli@ubs.com; Maciej

More information

Sustainable investing

Sustainable investing Sustainable investing Investing for Good Michaela Seimen Howat, CIO Sustainable Investing, UBS Wealth Management September 2018 Sustainable & Impact investments are investments made with the intention

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Are bond traders better than economists? Chief Investment Office WM 01 August 2018 3:49 pm BST Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com No, bond traders

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Are trade taxes changing trade? Chief Investment Office WM 21 November 2018 7:16 pm GMT Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com Globalization had peaked

More information

US equities. Will the Amazon, JP Morgan and Berkshire venture change healthcare?

US equities. Will the Amazon, JP Morgan and Berkshire venture change healthcare? Will the Amazon, JP Morgan and Berkshire venture change healthcare? Chief Investment Office WM 30 January 2018 6:17 pm GMT Jerome Brimeyer, Healthcare Equity Sector Strategist Americas; Bradley Ball, Financials

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Pride and Prejudice, and Economists Chief Investment Office WM 27 June 2018 10:54 pm BST Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com Pride month is a series

More information

Annual UBS investment Lecture. Welcome

Annual UBS investment Lecture. Welcome City Guest Wifi password: tglhkjni Annual UBS investment Lecture Thursday 17 November 2016 Welcome Public Economic and Investment Outlook Dean Turner, CFA Economist Chief Investment Office, WM November

More information

Chinese equities. A-shares join MSCI's index universe

Chinese equities. A-shares join MSCI's index universe A-shares join MSCI's index universe Chief Investment Office WM 21 June 2017 Hyde Chen, CFA, analyst, hyde.chen@ubs.com; Louisa Fok, CFA, analyst, louisa.fok@ubs.com MSCI has decided to include Chinese

More information

Global economy. Italy and the euro are investors lost in translation?

Global economy. Italy and the euro are investors lost in translation? Italy and the euro are investors lost in translation? Chief Investment Office WM 04 June 2018 10:51 pm BST Matteo Ramenghi, Chief Investment Officer UBS WM Italy, matteo.ramenghi@ubs.com; Ricardo Garcia,

More information

Future of food demand

Future of food demand Public Future of food demand Southeast Asia and Africa grain growers' brightest hope Mr. Wayne Gordon Executive Director April 2017 Agriculture's greatest challenge: Lower real returns Short term, agriculture

More information

Dr. Andreas Höfert, UBS Chief Economist. Swiss American Chamber of Commerce Zurich, October 30, 2009

Dr. Andreas Höfert, UBS Chief Economist. Swiss American Chamber of Commerce Zurich, October 30, 2009 UBS compensation survey Outlook 2010 Dr. Andreas Höfert, UBS Chief Economist Swiss American Chamber of Commerce Zurich, October 30, 2009 US equity markets: Havoc after Lehman Brothers collapse Index Percent

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Will recessions be less recessionary in the future? Chief Investment Office WM 25 July 2017 Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com Recessions tend to be

More information

CIO WM Research. Swiss Chartset Last update: 8 January 2014

CIO WM Research. Swiss Chartset Last update: 8 January 2014 CIO WM Research Swiss Chartset Last update: 8 January 2014 Contents Section 1 Economy 2 Section 2 Prices, Interest Rates, Exchange Rates, Monetary Indicators 27 Section 3 Switzerland in international comparison

More information

UBS CIO Houseview and Year ahead

UBS CIO Houseview and Year ahead UBS CIO Houseview and Year ahead November 2017 Themis Themistocleous Head, European CIO November 2017 Section 1: Global outlook and positioning CIO key view Global growth is accelerating Real GDP growth

More information

Becton Dickinson & Co

Becton Dickinson & Co 09/17E UBS 214 224 255 257 950 1042 1110 Becton Dickinson & Co UnitedStatesofAmerica/HealthcareEquipment &Supplies 2February2017 UBS Research Jonathan Groberg, IB Analyst Harris Iqbal Solidquarter,despiteFX

More information

UBS House View. Treasurers Forum the year ahead. November Chief Investment Office WM. Published 3 November 2015

UBS House View. Treasurers Forum the year ahead. November Chief Investment Office WM. Published 3 November 2015 UBS House View Chief Investment Office WM Treasurers Forum the year ahead November 2015 Published 3 November 2015 This report has been prepared by UBS AG. Please see the important disclaimer at the end

More information

Global economy. Is a trade war likely? The trade debate in May

Global economy. Is a trade war likely? The trade debate in May Is a trade war likely? The trade debate in May Chief Investment Office WM 08 May 2018 8:17 pm BST Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com; Yifan Hu, Regional CIO and Chief China Economist,

More information

Teva Pharmaceuticals

Teva Pharmaceuticals UBS 520 590 560 Israel/Pharmaceuticals 6January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst 2017GuidanceWorseThanExpected Our takeaway: Still so many questions Additional takeaway Thoughts

More information

UBS Outlook Switzerland

UBS Outlook Switzerland UBS Outlook Switzerland Outlook 2019 November 2018 Chief Investment Office GWM Financial analysis Short version For investors domiciled in Switzerland UBS Outlook Switzerland 4Q 2018 Please see the important

More information

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 10February2017. PositiveXareltoStudyAddsTailwindtoPharma Estimates

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 10February2017. PositiveXareltoStudyAddsTailwindtoPharma Estimates 12/17E UBS 180 188 178 153 700 749 792 Johnson & Johnson UnitedStatesofAmerica/Pharmaceuticals 10February2017 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst PositiveXareltoStudyAddsTailwindtoPharma

More information

European economy. Spain: A fading tourism boom

European economy. Spain: A fading tourism boom Spain: A fading tourism boom Chief Investment Office WM 07 May 2018 4:29 pm BST Roberto Scholtes Ruiz, Chief Investment Officer Spain, roberto.ruiz-scholtes@ubs.com Tourist arrivals to Spain rose notably

More information

Baxter International Inc.

Baxter International Inc. ...12/17E..From. Baxter International Inc. UnitedStatesofAmerica/Equipment&Services 1February2017 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst PostQ3CallTakeaways Solid beat, outlook calls

More information

Bristol-Myers Squibb

Bristol-Myers Squibb 12/16E UBS 074 069 077 068 288 300 310 Bristol-Myers Squibb UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst 4QMiss;NumbersComingDownSome

More information

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016. SlightlyBetterThanExpected2017Guidance

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016. SlightlyBetterThanExpected2017Guidance 12/16E UBS 083 086 088 097 354 400 440 Lilly (Eli) & Co UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst SlightlyBetterThanExpected2017Guidance

More information

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 15February2017. Q1U.S.PharmaTrendsOfftoaStrongStart

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 15February2017. Q1U.S.PharmaTrendsOfftoaStrongStart 12/17E UBS 180 188 178 153 700 749 792 Johnson & Johnson UnitedStatesofAmerica/Pharmaceuticals 15February2017 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst Q1USPharmaTrendsOfftoaStrongStart

More information

Bristol-Myers Squibb

Bristol-Myers Squibb ...12/17E..From. Bristol-Myers Squibb UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 1February2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst EUGenericSprycelImpactShouldBeModest

More information

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 9February2017. Q4&H2largelyinline.GuidanceOK.

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 9February2017. Q4&H2largelyinline.GuidanceOK. UBS 7964 8670 9366 Smith & Nephew UnitedKingdom/HealthcareEquipment& Supplies 9February2017 UBS Research Ian Douglas-Pennant, IB Analyst Sebastian Walker, IB Analyst Q4&H2largelyinlineGuidanceOK Q: How

More information

Sanofi. France/Pharmaceuticals 16February2017. ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained)

Sanofi. France/Pharmaceuticals 16February2017. ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained) ..From Sanofi France/Pharmaceuticals 16February2017 UBS Research Jack Scannell, IB Analyst Michael Leuchten, IB Analyst ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained) We are

More information

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017. In-Line4Q;GuidanceWeakerduetoFX

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017. In-Line4Q;GuidanceWeakerduetoFX 12/16E UBS 067 064 061 048 240 265 285 Pfizer Inc UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst In-Line4Q;GuidanceWeakerduetoFX

More information

Novo Nordisk. Denmark/Pharmaceuticals 19January2017. Amicrosegmentationofdiabetesdynamics

Novo Nordisk. Denmark/Pharmaceuticals 19January2017. Amicrosegmentationofdiabetesdynamics UBS 1522 1623 1803 Novo Nordisk Denmark/Pharmaceuticals 19January2017 UBS Research Michael Leuchten, IB Analyst Jack Scannell, IB Analyst Amicrosegmentationofdiabetesdynamics One rule does not fit all

More information

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017. AddingAnotherStrategicAsset

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017. AddingAnotherStrategicAsset 12/16E UBS 083 086 088 100 357 415 440 Lilly (Eli) & Co UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst AddingAnotherStrategicAsset

More information

Sanofi. France/Pharmaceuticals 13December2016. Lowpharmapricingpoweroffsetbylow expectations.maintainneutralrating

Sanofi. France/Pharmaceuticals 13December2016. Lowpharmapricingpoweroffsetbylow expectations.maintainneutralrating UBS 589 570 589 Sanofi France/Pharmaceuticals 13December2016 UBS Research Jack Scannell, IB Analyst Michael Leuchten, IB Analyst Lowpharmapricingpoweroffsetbylow expectationsmaintainneutralrating Today

More information

Novartis. Switzerland/Pharmaceuticals 22March2017. AnotherCV-shapedstumblingblockinpursuitof pharmatop-linegrowth

Novartis. Switzerland/Pharmaceuticals 22March2017. AnotherCV-shapedstumblingblockinpursuitof pharmatop-linegrowth UBS 472 478 534 Novartis Switzerland/Pharmaceuticals 22March2017 UBS Research Michael Leuchten, IB Analyst Jack Scannell, IB Analyst AnotherCV-shapedstumblingblockinpursuitof pharmatop-linegrowth This

More information

UBS House View. Preparing for the second half. Monthly Letter. Risks ahead. First half scorecard. Shifting growth.

UBS House View. Preparing for the second half. Monthly Letter. Risks ahead. First half scorecard. Shifting growth. UBS House View Monthly Letter 21 June 218 Chief Investment Office GWM Investment Research First half scorecard Risks ahead Shifting growth Asset allocation Global stocks managed to grind higher in the

More information

Bristol-Myers Squibb

Bristol-Myers Squibb 12/16E UBS 074 069 077 070 290 300 310 Bristol-Myers Squibb UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 6December2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst ThinkingAboutIO/ChemoGiven2-YrOpdivo

More information

UBS House View. a b. Plans are Worthless. Monthly Letter

UBS House View. a b. Plans are Worthless. Monthly Letter UBS House View Monthly Letter Chief Investment Office WM 16 November 217 Planning for downturns We believe the chances of recession and a bear market in coming months are limited. Still, we seek strategies

More information

AstraZeneca. UnitedKingdom/Pharmaceuticals 10January2017. MYSTIC:Whythetrialisnovel,whatendpointsto expect,andwhat"good"resultswouldlooklike

AstraZeneca. UnitedKingdom/Pharmaceuticals 10January2017. MYSTIC:Whythetrialisnovel,whatendpointsto expect,andwhatgoodresultswouldlooklike UBS 436 382 411 AstraZeneca UnitedKingdom/Pharmaceuticals 10January2017 UBS Research Jack Scannell, IB Analyst Michael Leuchten, IB Analyst MYSTIC:Whythetrialisnovel,whatendpointsto expect,andwhat"good"resultswouldlooklike

More information

Precious metals. A precious basket

Precious metals. A precious basket A precious basket Chief Investment Office WM 15 March 2018 Wayne Gordon, Analyst, wayne.gordon@ubs.com; Giovanni Staunovo, Analyst, giovanni.staunovo@ubs.com; Dominic Schnider, CFA, CAIA, Analyst, dominic.schnider@ubs.com

More information

Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7)

Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7) For Professional Clients/Institutional Investors Only Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7) 1. Introduction The European

More information

Swiss Quarterly: On the right track

Swiss Quarterly: On the right track Economic and Financial Analysis 10 July 2018 Global Economics 10 July 2018 Article Swiss Quarterly: On the right track Even though Switzerland s real GDP growth lost some momentum, the outlook is positive

More information

Flash Note Switzerland: Q2 GDP growth

Flash Note Switzerland: Q2 GDP growth FLASH NOTE Flash Note Switzerland: Q2 GDP growth The devil is in the details Pictet Wealth Management - Asset Allocation & Macro Research 7 September 2018 Yes, the Swiss economy is booming. GDP grew by

More information

AMS AG. Austria/Semiconductors&Semiconductor Equipment 26September2018 6:18pmGMT+1:00. Uncertaintyandmarginpressurekeepsus.

AMS AG. Austria/Semiconductors&Semiconductor Equipment 26September2018 6:18pmGMT+1:00. Uncertaintyandmarginpressurekeepsus. ..From AMS AG Austria/Semiconductors&Semiconductor Equipment 26September2018 6:18pmGMT+1:00 UBS Research David Mulholland, IB Analyst Francois-Xavier Bouvignies, IB Analyst Uncertaintyandmarginpressurekeepsus

More information

Longer Term Investments

Longer Term Investments The economics behind long-term themes Chief Investment Office WM 20 February 2018 4:15 pm GMT Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com; Philippe G. Müller, CIIA, Head Global Investment

More information

1. Introduction. 2. Client Profitability

1. Introduction. 2. Client Profitability For Professional Clients/Institutional Investors Only Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7) and Markets in Financial

More information

Direct Execution UBS ATS. Rules of Engagement Addendum for Conditional Indications

Direct Execution UBS ATS. Rules of Engagement Addendum for Conditional Indications Direct Execution UBS ATS Rules of Engagement Addendum for Conditional Indications March 14, 2017 UBS RoE Addendum 03142017.docx Table of Contents 1 Introduction 1 2 Overview 1 2.1 Initial Transmission

More information

CIO Monthly Letter. Teaming up to perform

CIO Monthly Letter. Teaming up to perform Chief Investment Office WM 26 June 2014 Teaming up to perform Mark Haefele Global Chief Investment Officer Wealth Management Tactically, we are overweight US and Eurozone equities, and US high yield and

More information

Flash Note Euro area: Q2 GDP growth

Flash Note Euro area: Q2 GDP growth FLASH NOTE Flash Note Euro area: Q2 GDP growth Revising our 2018 GDP growth forecast down to 2.0% Pictet Wealth Management - Asset Allocation & Macro Research 31 July 2018 Euro area GDP growth unexpectedly

More information

Global Research February 2017

Global Research February 2017 Global Research February 2017 Discussion of "Reciprocal Lending Relationships in Shadow Banking" by Yi Li and "Nonbank and Lending Standards in Mortgage Markets. The Spillovers from Liquidity Regulation."

More information

Biogen Idec Inc. UnitedStatesofAmerica/Pharmaceuticals 21April2017. PositiveCHMPRecommendationonSpinraza

Biogen Idec Inc. UnitedStatesofAmerica/Pharmaceuticals 21April2017. PositiveCHMPRecommendationonSpinraza 12/17E UBS 496 513 528 533 2070 2225 2365 Biogen Idec Inc UnitedStatesofAmerica/Pharmaceuticals 21April2017 UBS Research Carter Gould, IB Analyst Jeffrey Hung, IB Analyst PositiveCHMPRecommendationonSpinraza

More information

UBS House View. Key Messages. Investor spotlight

UBS House View. Key Messages. Investor spotlight UBS House View United Weekly 12 February 2018 States Chief Investment Office WM Week Ahead Will US inflation data soothe or agitate markets? With bond markets in an anxious mood, the January consumer price

More information

UBS Economics Day The Australian Budget

UBS Economics Day The Australian Budget UBS Economics Day The Australian 2015-16 Budget Andrew Lilley Interest Rate Strategist andrew.lilley@ubs.com This document has been prepared by UBS Securities Australia Ltd. ANALYST CERTIFICATION AND REQUIRED

More information

VAT Group N. Switzerland/Machinery 11December2017. Wenowexpectpositiveorganicgrowthin2019Econsensusupgradecycletocontinue

VAT Group N. Switzerland/Machinery 11December2017. Wenowexpectpositiveorganicgrowthin2019Econsensusupgradecycletocontinue ..From VAT Group N Switzerland/Machinery 11December2017 UBS Research Joe Iffert, IB Analyst David Mulholland, IB Analyst Wenowexpectpositiveorganicgrowthin2019Econsensusupgradecycletocontinue We increase

More information

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 16April2017. BaricitinibDisappointment

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 16April2017. BaricitinibDisappointment 12/17E UBS 097 103 105 110 415 445 495 Lilly (Eli) & Co UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 16April2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst BaricitinibDisappointment

More information

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 25April2017. SolidStartTotheYear

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 25April2017. SolidStartTotheYear 12/17E UBS 097 103 105 110 415 445 495 Lilly (Eli) & Co UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 25April2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst SolidStartTotheYear

More information

European economy. Italy: Politics remain complex, but systemic risks abate

European economy. Italy: Politics remain complex, but systemic risks abate Italy: Politics remain complex, but systemic risks abate Chief Investment Office WM 11 July 2017 10:05 am BST Matteo Ramenghi, strategist, matteo.ramenghi@ubs.com; Thomas Wacker, CFA, analyst, thomas.wacker@ubs.com;

More information

FLASH NOTE EURO AREA: ECONOMIC ACTIVITY WHAT IF CAR TARIFFS LIE AHEAD? SUMMARY

FLASH NOTE EURO AREA: ECONOMIC ACTIVITY WHAT IF CAR TARIFFS LIE AHEAD? SUMMARY Author NADIA GHARBI, CFA ngharbi@pictet.com SUMMARY Among the key risks for our euro area outlook, the threat of US auto tariffs is of major importance. The US Commerce Department s investigation on national

More information

Chief Investment Office GWM Investment Research. Cantonal Competitiveness Indicator

Chief Investment Office GWM Investment Research. Cantonal Competitiveness Indicator Chief Investment Office GWM Investment Research Cantonal Competitiveness Indicator 218 Contents 3 Editorial 4 High concentration of growth potential 6 The eight pillars of competitiveness 9 Cantonal competitiveness

More information

Sharp pickup in gold demand in Q4 last year

Sharp pickup in gold demand in Q4 last year Author LUC LUYET lluyet@pictet.com SUMMARY The fourth quarter of last year saw a strong upsurge in the gold price thanks to a sharp increase in investment demand. Besides seasonally strong jewellery demand

More information

Takeda Pharmaceutical

Takeda Pharmaceutical UBS 1105 786 571 Takeda Pharmaceutical Japan/Pharmaceuticals 30March2017 UBS Research Atsushi Seki, IB Analyst Whatistheconfidencelevelformargin expansion? The market is getting optimistic on Takeda Pharma

More information

Longer Term Investments

Longer Term Investments Automation and robotics - Spotlight on artificial intelligence Chief Investment Office WM 22 August 2016 Sundeep Gantori, CFA, CAIA, analyst, sundeep.gantori@ubs.com; Alexander Stiehler, CFA, analyst,

More information

Flash Note Currencies: EUR/USD

Flash Note Currencies: EUR/USD FLASH NOTE Flash Note Currencies: EUR/USD Short-term hurdles to euro strength Pictet Wealth Management - Asset Allocation & Macro Research 18 June 2018 The ECB s commitment on rates announced at its June

More information

Flash Note Japan: Second reading of Q2 GDP

Flash Note Japan: Second reading of Q2 GDP FLASH NOTE Flash Note Japan: Second reading of Q2 GDP GDP forecast revised up but external uncertainties persist Pictet Wealth Management - Asset Allocation & Macro Research 11 September 2018 The second

More information

Eurozone. EY Eurozone Forecast December 2013

Eurozone. EY Eurozone Forecast December 2013 Eurozone EY Eurozone Forecast December 213 Austria Belgium Cyprus Estonia Finland France Germany Greece Ireland Italy Luxembourg Malta Netherlands Portugal Slovakia Slovenia Spain Outlook for Germany Strong

More information

Flash Economics. The acceleration in global trade is very good for the euro zone; what accounts for it?

Flash Economics. The acceleration in global trade is very good for the euro zone; what accounts for it? 1 July 17 - The acceleration in global trade is very good for the euro zone; what accounts for it? Since the second half of 1, global trade in volume terms has accelerated, lifting euro-zone exports. First,

More information

FLASH NOTE EUROPE CHART OF THE WEEK: GERMAN GROWTH A BLIP OR SOMETHING MORE? SUMMARY

FLASH NOTE EUROPE CHART OF THE WEEK: GERMAN GROWTH A BLIP OR SOMETHING MORE? SUMMARY Author NADIA GHARBI, CFA ngharbi@pictet.com SUMMARY German GDP figures showed that the German economy contracted in Q3 for the first time since Q1 2015 but markets were prepared. Economic activity was

More information

Eurozone Economic Watch. July 2018

Eurozone Economic Watch. July 2018 Eurozone Economic Watch July 2018 Eurozone: A shift to more moderate growth with increased downward risks BBVA Research - Eurozone Economic Watch July 2018 / 2 Hard data improved in May but failed to recover

More information

Atradius Country Report. Main Western European Markets - May 2018

Atradius Country Report. Main Western European Markets - May 2018 Atradius Country Report Main Western European Markets - May 8 Contents Austria Belgium Denmark 7 France 9 Germany Ireland Italy The Netherlands 7 Spain 9 Sweden Switzerland United Kingdom Print all Austria

More information

ANZ QUICK REACTION INTERNATIONAL TRAVEL & MIGRATION SEPTEMBER Market relevance: Medium

ANZ QUICK REACTION INTERNATIONAL TRAVEL & MIGRATION SEPTEMBER Market relevance: Medium ANZ Quick Reaction / 21 October 214 / 1 of 6 Contributor Mark Smith Senior Economist Telephone: +64 9 357 496 E-mail: Mark.Smith2@anz.com INTERNATIONAL TRAVEL & MIGRATION SEPTEMBER 214 Market relevance:

More information

Eurozone. EY Eurozone Forecast September 2014

Eurozone. EY Eurozone Forecast September 2014 Eurozone EY Eurozone Forecast September 2014 Austria Belgium Cyprus Estonia Finland France Germany Greece Ireland Italy Latvia Luxembourg Malta Netherlands Portugal Slovakia Slovenia Spain Outlook for

More information

In particular, we want to see whether: We find: The causes appear to be:

In particular, we want to see whether: We find: The causes appear to be: 1 January 17 - Are we able to explain the trends in employment and unemployment in France in 1? In France, 1 was marked by fairly modest growth and a fairly significant fall in unemployment, which is surprising.

More information

Eurozone. EY Eurozone Forecast March 2014

Eurozone. EY Eurozone Forecast March 2014 Eurozone EY Eurozone Forecast March 2014 Austria Belgium Cyprus Estonia Finland France Germany Greece Ireland Italy Latvia Luxembourg Malta Netherlands Portugal Slovakia Slovenia Spain Outlook for Germany

More information

Closed-end fund update

Closed-end fund update ab Closed-end fund update Update on Convertible Funds: Asset Composition UBS Wealth Management Research / 29 July 2008 Lead Analyst Sangeeta Marfatia Highlights In recent weeks we have seen pressure from

More information

Quarterly Macro Report

Quarterly Macro Report Quarterly Macro Report 3rd Quarter 218 Even though forward-looking indicators for the industrialized countries still point to an acceleration of growth, the outlook for the global economy has deteriorated

More information

Flash Economics. Euro zone and France: No one can now deny that it is supply-side policies that are needed.

Flash Economics. Euro zone and France: No one can now deny that it is supply-side policies that are needed. November - and : No one can now deny that it is supply-side policies that are needed There is still a debate in the euro zone and about the alleged need to continue to conduct demand-stimulating policies:

More information

UBS CIO Monthly Letter

UBS CIO Monthly Letter ab Chief Investment Officer Wealth Management August 213 UBS CIO Monthly Letter The changing winds Alexander S. Friedman Global CIO UBS WM Summer has finally arrived in Europe, and many of us are heading

More information

Portfolio principles. Loss-harvesting to save taxes 4 October begin on page 4.

Portfolio principles. Loss-harvesting to save taxes 4 October begin on page 4. Loss-harvesting to save taxes 4 October 2018 Chief Investment Office Americas, Wealth Management Kathleen McNamara, CFA, CFP, Senior Municipal Strategist Americas, kathleen.mcnamara@ubs.com We provide

More information

French Election Watch

French Election Watch En Marche! CIO WM Research 7 May 2017 Dean Turner, CFA, economist; Ricardo Garcia, economist; Themis Themistocleous, Regional CIO Europe; Thomas Wacker, CFA, analyst; Bert Jansen, strategist; Thomas Flury,

More information

Novo Nordisk. Denmark/Pharmaceuticals 7December2016. Doubleupgrade

Novo Nordisk. Denmark/Pharmaceuticals 7December2016. Doubleupgrade Denmark/Pharmaceuticals 7December2016 UBS Research Jack Scannell, IB Analyst Michael Leuchten, IB Analyst Doubleupgrade If Novo is a large cap pharma now, it's a good one Price pressure yes, doomsday no

More information

World Economic outlook

World Economic outlook Frontier s Strategy Note: 01/23/2014 World Economic outlook IMF has just released the World Economic Update on the 21st January 2015 and we are displaying the main points here. Even with the sharp oil

More information

FLASH NOTE CHINA: SHIFTING BALANCE OF PAYMENT CONSISTENT CURRENT ACCOUNT SURPLUS IS BEHIND US SUMMARY

FLASH NOTE CHINA: SHIFTING BALANCE OF PAYMENT CONSISTENT CURRENT ACCOUNT SURPLUS IS BEHIND US SUMMARY CONSISTENT CURRENT ACCOUNT SURPLUS IS BEHIND US Author DONG CHEN dochen@pictet.com SUMMARY In the first three quarters of the year, China ran a current account deficit of USD12.8 billion. It looks likely

More information

Energy. North American energy independence: reenergized 22 March disclosures that begin on page 5.

Energy. North American energy independence: reenergized 22 March disclosures that begin on page 5. North American energy independence: reenergized 22 March 2016 CIO WM Research Nicole Decker, Equity Sector Strategist, nicole.decker@ubs.com; David Lefkowitz, CFA, Senior Equity Strategist, david.lefkowitz@ubs.com

More information

Novartis. Switzerland/Pharmaceuticals 20April2017. Alconreviewseemson

Novartis. Switzerland/Pharmaceuticals 20April2017. Alconreviewseemson ...UBS.4.87.5.33.5.55 Novartis Switzerland/Pharmaceuticals 20April2017 UBS Research Michael Leuchten, IB Analyst Jack Scannell, IB Analyst Alconreviewseemson Bloomberg reports (20/04/17) that Novartis

More information

Seventh City of London Biennial Meeting 2013

Seventh City of London Biennial Meeting 2013 Seventh City of London Biennial Meeting 2013 Looking Ahead with Optimism and Realism The World in Recovery: Global Currency Trends George Athanasopoulos Group Managing Director Co-Head of Global Foreign

More information